Zylö’s ‘Powered By Z-pod’ Technology Featured in Peer-Reviewed Paper Published in Experimental Dermatology
GREENVILLE, SC, Sept. 27, 2023 (GLOBE NEWSWIRE) -- The Z-pod® topical delivery platform was used in various in vivo studies that were highlighted in a peer-reviewed paper just published online by Experimental Dermatology titled, “Nano-encapsulated anandamide (AEA) reduces inflammatory cytokines in vitro and lesion severity in a murine model of cutaneous lupus erythematosus [CLE].”
- His colleagues at George Washington University (GWU) and AECOM wrote the paper, designed the studies, and performed some of the studies.
- Approximately 500,000 people in the U.S. suffer from cutaneous lupus erythematosus (CLE), with a significant impact on quality of life.
- Moreover, the technology enables the use of a novel active ingredient that otherwise would not be an effective tool in managing this disease.
- The principal investigator of the grant-work is Zylö’s A. Draganski, and the primary collaborator is Dr. Werth.